Evidence map›Paper›PMID 28105518›Full record

ArticleDiabetologia2017

Associations between hepatic miRNA expression, liver triacylglycerols and gut microbiota during metabolic adaptation to high-fat diet in mice.

Vincent Blasco-Baque, Berengère Coupé, Aurelie Fabre, Sandra Handgraaf, Pierre Gourdy, Jean-François Arnal, Michael Courtney, Carole Schuster-Klein, Beatrice Guardiola, François Tercé and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Diabetologia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Gut microbiome in gastrointestinal cancer: a friend or foe?International journal of biological sciences · 2022
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Vincent Blasco-BaqueInstitut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France.
Berengère CoupéVaiomer SAS, Labège, France.
Aurelie FabreInstitut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France.
Sandra HandgraafInstitut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France.
Pierre GourdyInstitut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France.
Jean-François ArnalInstitut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France.
Michael CourtneyVaiomer SAS, Labège, France.
Carole Schuster-KleinPôle d'Innovation Thérapeutique Métabolisme, Recherche de Découvertes, Institut de Recherches Servier, Suresnes, France.
Beatrice GuardiolaPôle d'Innovation Thérapeutique Métabolisme, Recherche de Découvertes, Institut de Recherches Servier, Suresnes, France.
François TercéInstitut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France.
Rémy BurcelinInstitut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France.
Matteo SerinoInstitut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France. matteo.serino@inserm.fr.
Inserm · FRInstitut des Maladies Métaboliques et Cardiovasculaires · FRPlateforme Technologique d'Innovation Biomédicale · FRServier (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisDespite the current pandemic of metabolic diseases, our understanding of the diverse nature of the development of metabolic alterations in people who eat a high-fat diet (HFD) is still poor. We recently demonstrated a cardio-metabolic adaptation in mice fed an HFD, which was characterised by a specific gut and periodontal microbiota profile. Since the severity of hepatic disease is characterised by specific microRNA (miRNA) signatures and the gut microbiota is a key driver of both hepatic disease and miRNA expression, we analysed the expression of three hepatic miRNA and studied their correlation with hepatic triacylglycerol content and gut microbiota.

methodsTwo cohorts of C57BL/6 4-week-old wild-type (WT) male mice (n = 62 and n = 96) were fed an HFD for 3 months to provide a model of metabolic adaptation. Additionally 8-week-old C57BL/6 mice, either WT or of different genotypes, with diverse gut microbiota (ob/ob, Nod1, Cd14 knockout [Cd14KO] and Nod2) or without gut microbiota (axenic mice) were fed a normal chow diet. Following which, glycaemic index, body weight, blood glucose levels and hepatic triacylglycerol levels were measured. Gut (caecum) microbiota taxa were analysed by pyrosequencing. To analyse hepatic miRNA expression, real-time PCR was performed on total extracted miRNA samples. Data were analysed using two-way ANOVA followed by the Dunnett's post hoc test, or by the unpaired Student's t test. A cluster analysis and multivariate analyses were also performed.

resultsOur results demonstrated that the expression of miR-181a, miR-666 and miR-21 in primary murine hepatocytes is controlled by lipopolysaccharide in a dose-dependent manner. Of the gut microbiota, Firmicutes were positively correlated and Proteobacteria and Bacteroides acidifaciens were negatively correlated with liver triacylglycerol levels. Furthermore, the relative abundance of Firmicutes was negatively correlated with hepatic expression of miR-666 and miR-21. In contrast, the relative abundance of B. acidifaciens was positively correlated with miR-21. CONCLUSIONS/

interpretationWe propose the involvement of hepatic miRNA, liver triacylglycerols and gut microbiota as a new triad that underlies the molecular mechanisms by which gut microbiota governs hepatic pathophysiology during metabolic adaptation to HFD.

Indexed as

AnimalsDiet, High-FatGastrointestinal MicrobiomeGenotypeHepatocytesLipopolysaccharide ReceptorsLipopolysaccharidesLiverMaleMiceMice, Inbred C57BLMice, KnockoutMicroRNAsNod1 Signaling Adaptor ProteinNod2 Signaling Adaptor ProteinPolymerase Chain ReactionLipopolysaccharide ReceptorsLipopolysaccharidesMicroRNAsNod1 protein, mouseNod1 Signaling Adaptor ProteinNod2 protein, mouseNod2 Signaling Adaptor ProteinTriglyceridesGut microbiotaHigh-fat dietLiver triacylglycerol contentMetabolic adaptationMetabolic diseasesmiRNA

Identifiers

PMID28105518
PMCPMC6518927
OpenAlexW2579222391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.